Background: Solid organ transplantation (SOT) frequently is complicated by cytomegalovirus
(CMV) infections. Cidofovir (CDV) is active against CMV, including many ganciclovir (GCV) …

The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and
disease progression. The clinical significance of such resistance in solid-organ …

Ganciclovir (DHPG) was used to treat eight patients with severe cytomegalovirus (CMV)
disease after renal transplantation. Four had generalized disease, one had severe recurrent …

Background Treatment of ganciclovir‐resistant (GCV‐R)/refractory cytomegalovirus (CMV)
infections in blood/marrow transplant (BMT) and solid organ transplant (SOT) recipients …

Cytomegalovirus (CMV) is the single most important pathogen affecting solid organ
transplant (SOT) recipients. CMV may occur as a primary infection in CMV-naïve patients …

Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CMV)
infections in 22 heart and heart-lung transplant recipients at six medical centers was …

Cytomegalovirus (CMV) infection is the most common infectious complication following solid
organ transplantation. Ganciclovir (GCV)‐resistant CMV infection may be fatal, and is difficult …

MATERIALS AND METHODS Seventeen patients–12 who had received orthotopic liver
transplants and 5 who had orthotopic kidney transplants at our institution–received …

Though an important cause of morbidity and mortality in solid organ transplantation (SOT),
the long-term outcomes of cytomegalovirus (CMV) disease treatment have not been well …

Background. The optimal regimen for the prevention and treatment of cytomegalovirus
(CMV) disease in solid organ transplant recipients remains to be defined, particularly for …